RegeneRX Biopharmaceuticals (RGRX.OB) Shares Up on Financing News
Finding funding can be a difficult and often detrimental to share value for many developmental companies. Often times, discounted rates are required to current share price with value being derived from the bid price. Of course, shareholders often scream “dilution” and are disgusted by the concept. Unfortunately, it is a necessary evil the majority of the time as cash is required to expand developments of companies. When a company can secure financing that is at a premium to share price and work deals for options or warrants that are not detrimental to the share structure, investors should be enthusiastic. This…